Your browser doesn't support javascript.
loading
Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.
Franken, M D; van Rooijen, E M; May, A M; Koffijberg, H; van Tinteren, H; Mol, L; Ten Tije, A J; Creemers, G J; van der Velden, A M T; Tanis, B C; Uyl-de Groot, C A; Punt, C J A; Koopman, M; van Oijen, M G H.
Afiliación
  • Franken MD; University Medical Center Utrecht, Department of Medical Oncology, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.
  • van Rooijen EM; Institute for Medical Technology Assessment/Institute of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.
  • May AM; Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.
  • Koffijberg H; Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands; Department of Health Technology & Services Research, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, P.O. Box 217, 7500
  • van Tinteren H; The Netherlands Cancer Institute, Department of Biostatistics, P.O. Box 90203, 1006 BE Amsterdam, The Netherlands.
  • Mol L; Netherlands Comprehensive Cancer Organization, P.O. Box 1281, 6501 BG Nijmegen, The Netherlands.
  • Ten Tije AJ; Amphia Hospital, Department of Medical Oncology, P.O. Box 90158, 4800 RK Breda, The Netherlands.
  • Creemers GJ; Catharina Hospital, Department of Medical Oncology, P.O. Box 1350, 5602 ZA Eindhoven, The Netherlands.
  • van der Velden AMT; Tergooi Hospital, Department of Medical Oncology, P.O. Box 10016, 1201 DA Hilversum, The Netherlands.
  • Tanis BC; Groene Hart Hospital, Department of Medical Oncology, P.O. Box 1098, 2800 BB Gouda, The Netherlands.
  • Uyl-de Groot CA; Institute for Medical Technology Assessment/Institute of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.
  • Punt CJA; Academic Medical Center, Department of Medical Oncology, University of Amsterdam, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands.
  • Koopman M; University Medical Center Utrecht, Department of Medical Oncology, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.
  • van Oijen MGH; Academic Medical Center, Department of Medical Oncology, University of Amsterdam, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands. Electronic address: m.g.vanoijen@amc.uva.nl.
Eur J Cancer ; 75: 204-212, 2017 04.
Article en En | MEDLINE | ID: mdl-28237866
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Capecitabina / Bevacizumab / Antineoplásicos Tipo de estudio: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Eur J Cancer Año: 2017 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Capecitabina / Bevacizumab / Antineoplásicos Tipo de estudio: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Eur J Cancer Año: 2017 Tipo del documento: Article País de afiliación: Países Bajos